Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review

Zhixiang Gao; Lu Jin; Haijun Lv; Nengliang Duan; Guoneng Zhang; Yuanshuai Ran; Boxin Xue; Xiaolong Liu

doi:10.1016/j.eucr.2024.102722

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review

Urol Case Rep. 2024 Mar 28:54:102722. doi: 10.1016/j.eucr.2024.102722. eCollection 2024 May.

Authors

Zhixiang Gao^{1

2}, Lu Jin², Haijun Lv³, Nengliang Duan², Guoneng Zhang², Yuanshuai Ran², Boxin Xue², Xiaolong Liu²

Affiliations

¹ Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, China.
² Department of Urology, The Second Affiliated Hospital of Soochow University, China.
³ Department of Pathology, The Second Affiliated Hospital of Soochow University, China.

Abstract

In recent years, with the in-depth study of PD-1/PD-L1 related pathways, great progress has been made in cancer immunotherapy. However, the immunotherapy regimen for mccRCC is still controversial in clinical practice. A 50-year-old man with mccRCC complicated with renal venous tumor thrombus from 2019 to present, including surgical treatment, targeted therapy and the combined treatment regimen of "Tislelizumab combined with Sunitinib". Although he experienced a roller coaster of adverse reactions during treatment, the patient's prognosis was good. Tislelizumab combined with Sunitinib is safe and effective in the Treatment of mccRCC.

Keywords: Immunotherapy; Targeted therapy; Tislelizumab; mccRCC.

Publication types

Case Reports